{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:27:49Z","timestamp":1790267269355,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,12,15]],"date-time":"2013-12-15T00:00:00Z","timestamp":1387065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,12,15]],"date-time":"2013-12-15T00:00:00Z","timestamp":1387065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s10637-013-0057-2","type":"journal-article","created":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T02:23:34Z","timestamp":1386987814000},"page":"355-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer"],"prefix":"10.1007","volume":"32","author":[{"given":"Yoon-Koo","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Nishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukimasa","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Akinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,15]]},"reference":[{"key":"57_CR1","unstructured":"Ferlay J, Shin HR, Bray F et al. (2008) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer, 12\/2010 update. http:\/\/globocan.iarc.fr"},{"key":"57_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687\u2013697","journal-title":"Lancet"},{"key":"57_CR3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1470-2045(09)70136-6","volume":"10","author":"R Wesolowski","year":"2009","unstructured":"Wesolowski R, Lee C, Kim R (2009) Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol 10:903\u2013912","journal-title":"Lancet Oncol"},{"key":"57_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc3205","volume":"12","author":"E Gherardi","year":"2012","unstructured":"Gherardi E, Birchmeier W, Birchmeier C et al (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89\u2013103","journal-title":"Nat Rev Cancer"},{"key":"57_CR5","first-page":"1517","volume":"25","author":"J Lee","year":"2011","unstructured":"Lee J, Seo JW, Jun HJ et al (2011) Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 25:1517\u20131524","journal-title":"Oncol Rep"},{"key":"57_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000065477","volume":"63","author":"H Amemiya","year":"2002","unstructured":"Amemiya H, Kono K, Itakura J et al (2002) c-Met expression in gastric cancer with liver metastasis. Oncology 63:286\u2013296","journal-title":"Oncology"},{"key":"57_CR7","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1200\/JCO.2011.36.7706","volume":"29","author":"F Graziano","year":"2011","unstructured":"Graziano F, Galluccio N, Lorenzini P et al (2011) Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29:4789\u20134795","journal-title":"J Clin Oncol"},{"key":"57_CR8","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.1200\/JCO.2011.35.4928","volume":"29","author":"JK Lennerz","year":"2011","unstructured":"Lennerz JK, Kwak EL, Ackerman A et al (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29:4803\u20134810","journal-title":"J Clin Oncol"},{"key":"57_CR9","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1007\/s002689900642","volume":"23","author":"SU Han","year":"1999","unstructured":"Han SU, Lee JH, Kim WH et al (1999) Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma. World J Surg 23:1176\u20131180","journal-title":"World J Surg"},{"key":"57_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nrclinonc.2012.71","volume":"9","author":"S Peters","year":"2012","unstructured":"Peters S, Adjei AA (2012) MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 9:314\u2013326","journal-title":"Nat Rev Clin Oncol"},{"key":"57_CR11","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-09-1173","volume":"9","author":"N Munshi","year":"2010","unstructured":"Munshi N, Jeay S, Li Y et al (2010) ARQ 197, a novel and selective inhibitor of the human cMet receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9:1544\u20131553","journal-title":"Mol Cancer Ther"},{"key":"57_CR12","doi-asserted-by":"publisher","first-page":"20666","DOI":"10.1074\/jbc.M110.213801","volume":"286","author":"S Eathiraj","year":"2011","unstructured":"Eathiraj S, Palma R, Volckova E et al (2011) Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 286:20666\u201320676","journal-title":"J Biol Chem"},{"key":"57_CR13","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1200\/JCO.2010.34.0570","volume":"29","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, von Pawel J, Garmey EG et al (2011) Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29:3307\u20133315","journal-title":"J Clin Oncol"},{"key":"57_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(12)70490-4","volume":"14","author":"A Santoro","year":"2013","unstructured":"Santoro A, Rimassa L, Borbath I et al (2013) Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 14:55\u201363","journal-title":"Lancet Oncol"},{"key":"57_CR15","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1177\/0091270004268128","volume":"44","author":"K Kim","year":"2004","unstructured":"Kim K, Johnson JA, Derendorf H (2004) Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 44:1083\u20131105","journal-title":"J Clin Pharmacol"},{"key":"57_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"57_CR17","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/annonc\/mdt014","volume":"24","author":"N Yamamoto","year":"2013","unstructured":"Yamamoto N, Murakami H, Nishina T et al (2013) The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. Ann Oncol 24:1653\u20131659","journal-title":"Ann Oncol"},{"key":"57_CR18","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1200\/JCO.2011.39.4585","volume":"30","author":"JH Kang","year":"2012","unstructured":"Kang JH, Lee SI, do Lim H et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513\u20131518","journal-title":"J Clin Oncol"},{"key":"57_CR19","first-page":"817","volume":"5","author":"CW Wu","year":"1998","unstructured":"Wu CW, Li AF, Chi CW et al (1998) Hepatocyte growth factor and Met\/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 5:817\u2013822","journal-title":"Oncol Rep"},{"issue":"8 Suppl","key":"57_CR20","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1158\/1538-7445.AM2012-1729","volume":"72","author":"S Rodig","year":"2012","unstructured":"Rodig S, Sequist LV, Schiller JH et al. (2012) An exploratory biomarker analysis evaluating the effect of the c-MET inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded phase 2 study. Cancer Res 72(8 Suppl): abstract 1729","journal-title":"Cancer Res"},{"key":"57_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1517\/13543784.2013.741586","volume":"22","author":"J Trojan","year":"2013","unstructured":"Trojan J, Zeuzem S (2013) Tivantinib in hepatocellular carcinoma. Expert Opin Investig Drugs 22:141\u2013147","journal-title":"Expert Opin Investig Drugs"},{"key":"57_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.18632\/oncotarget.718","volume":"4","author":"H Kawakami","year":"2013","unstructured":"Kawakami H, Okamoto I, Arao T et al (2013) MET amplification as a potential therapeutic target in gastric cancer. Oncotarget 4:9\u201317","journal-title":"Oncotarget"},{"key":"57_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1158\/2159-8290.CD-11-0175","volume":"1","author":"DV Catenacci","year":"2011","unstructured":"Catenacci DV, Henderson L, Xiao SY et al (2011) Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 1:573\u2013579","journal-title":"Cancer Discov"},{"key":"57_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1200\/JCO.2010.31.0367","volume":"29","author":"TA Yap","year":"2011","unstructured":"Yap TA, Olmos D, Brunetto AT et al (2011) Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 29:1271\u20131279","journal-title":"J Clin Oncol"},{"key":"57_CR25","doi-asserted-by":"publisher","first-page":"7754","DOI":"10.1158\/1078-0432.CCR-11-1002","volume":"17","author":"LS Rosen","year":"2011","unstructured":"Rosen LS, Senzer N, Mekhail T et al (2011) A phase I dose-escalation study of tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 17:7754\u20137764","journal-title":"Clin Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0057-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-013-0057-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0057-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0057-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:47:27Z","timestamp":1678510047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-013-0057-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,15]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["57"],"URL":"https:\/\/doi.org\/10.1007\/s10637-013-0057-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,15]]},"assertion":[{"value":"5 September 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}